Eqis Capital Management, Inc. Genprex, Inc. Transaction History

Eqis Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.37 - $1.04 $75 - $212	-204 Reduced 1.37%	14,642 $5,000
Q2 2023 Aug 14, 2023	BUY	$0.74 - $1.1 $10,986 - $16,330	14,846 New	14,846 $14,000
Q2 2022 Aug 08, 2022	SELL	$1.28 - $2.31 $13,167 - $23,762	-10,287 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.82 - $3.5 $349 - $672	-192 Reduced 1.83%	10,287 $23,000
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $594 - $1,325	-491 Reduced 4.48%	10,479 $14,000
Q3 2021 Nov 12, 2021	SELL	$2.59 - $3.36 $170 - $221	-66 Reduced 0.6%	10,970 $29,000
Q2 2021 Aug 12, 2021	SELL	$3.11 - $4.87 $71 - $112	-23 Reduced 0.21%	11,036 $37,000
Q1 2021 May 14, 2021	BUY	$3.66 - $7.67 $40,475 - $84,822	11,059 New	11,059 $48,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.